Format

Send to

Choose Destination
J Neuroimmunol. 2015 May 15;282:92-6. doi: 10.1016/j.jneuroim.2015.03.021. Epub 2015 Mar 28.

Intravenous immunoglobulin may reduce relapse frequency in neuromyelitis optica.

Author information

1
Department of Neurology, Kuala Lumpur Hospital, Malaysia. Electronic address: shivenda70@yahoo.com.
2
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcwhyi@nus.edu.sg.
3
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: Amy_QUEK@nuhs.edu.sg.
4
Department of Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore; Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore. Electronic address: mdcyuki@nus.edu.sg.

Abstract

OBJECTIVES:

To evaluate the use of intravenous immunoglobulin (IVIG) in preventing relapses in patients with neuromyelitis optica (NMO) and its spectrum disorders (NMOSDs).

METHODS:

Six NMO/NMOSD patients who were treated with IVIG induction dose followed by 2- to 3- monthly infusions were retrospectively identified. Annualized relapse rates (ARR) and Expanded Disability Status Scale (EDSS) pre- and post-IVIG were recorded.

RESULTS:

Median number of relapses and median ARR significantly reduced from 8.0 to 1.0 and 0.75 to 0.15 (p<0.05) respectively. Median EDSS of 6.5 remained the same. Median duration of treatment was 4.0 years.

CONCLUSION:

IVIG may be used to reduce the relapse frequency in patients with NMO/NMOSD.

KEYWORDS:

Intravenous immunoglobulin; Neuromyelitis optica; Neuromyelitis optica spectrum disorder; Relapse rate

PMID:
25903734
DOI:
10.1016/j.jneuroim.2015.03.021
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center